< Go Back

Han Dai, Ph.D.

CBO and Head of Investment

Previously, Han was Senior Director of New Ventures at Johnson & Johnson Innovation, responsible for developing and implementing Innovation strategies, creating a deep and credible network with innovators and entrepreneurs. Han also focuses on the identification and evaluation of external opportunities, supporting negotiations and playing a critical role in management of academic and industrial collaborations that have potential to impact J&J portfolio for the global markets. Prior to that, he held multiple roles with increasing responsibilities as Scientific Leader and GSK Fellow of Protein Degradation DPU/Future Pipeline Discovery team at GlaxoSmithKline US headquarter. Han has ~20 years’ experience in Pharma/Biotech industry with track records of successful leadership in small molecule & biologics drug discovery & development and high-profile publications. Han received his Ph.D. in Molecular Biophysics from UT Southwestern Medical Center as Frank and Sara McKnight fellow, and his B.S. in Biochemistry from Department for Intensive Instruction, Nanjing University. Han completed his postdoctoral training in Harvard Medical School and HHMI as Helen Hay Whitney fellow.